Search
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigationalAlmonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to t...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsRemibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigationalRemibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersLinzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigationalLinzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis. It is similar to ...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 SubstratesZiftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigationalZiftomenib is a potent and highly selective menin inhibitor. This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation wh...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 SubstratesPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalPirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of a...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP1A2 InhibitorsVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalVimseltinib is a small molecule kinase inhibitor targeting colony-stimulating factor 1 receptor (CSF1R). It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. It is intended to provide a sa...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesRilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorde...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesSebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat . Sebetralstat is the first and only oral ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesAficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigationalAficamten is a cardiac myosin inhibitor. Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symp...
Categories: Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 SubstratesZongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigationalZongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates